Clinical Trials

Find a Trial

Trial Summary

Protocol No.EA5142
StatusOPEN TO ACCRUAL
Principal InvestigatorJalal, Shadia
ScopeNational
PhasePhase III
Age GroupAdult
TitleAdjuvant Nivolumab in Resected Lung Cancers (ANVIL) ? A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
DescriptionThis randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Diagnosed with lung cancer and have undergone resection
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesLung Cancer, Non-Small Cell
Participating InstitutionsIndiana University (IU)
  • Eskenazi Hospital
  • Indiana University Hospital / IU Simon Cancer Center
Roudebush VA Medical Center
    Treatment TypeTreatment
    ContactMaggie Uhrich, RNPhone: 317-274-4505
    Pager: 317-312-3118
    Email: muhrich@iu.edu